MYOI

Myoia Therapeutics is a biotechnology company focused on developing precision medicines for the treatment of genetic and acquired muscle diseases, with a primary emphasis on cardiovascular conditions. The company leverages its expertise in muscle biology to design small molecule modulators that target the underlying mechanics of muscle contraction. Its lead programs are aimed at addressing hypertrophic cardiomyopathy (HCM) and other forms of heart failure by directly modulating cardiac myosin activity. By focusing on the molecular drivers of disease, Myoia aims to provide transformative therapies that improve cardiac function and patient outcomes. The company is currently advancing its pipeline through pre-clinical development stages.